Clinical characteristics and course of 63 patients with BRAF mutant lung cancers Journal Article


Authors: Litvak, A. M.; Paik, P. K.; Woo, K. M.; Sima, C. S.; Hellmann, M. D.; Arcila, M. E.; Ladanyi, M.; Rudin, C. M.; Kris, M. G.; Riely, G. J.
Article Title: Clinical characteristics and course of 63 patients with BRAF mutant lung cancers
Abstract: Introduction: Mutant BRAF is a driver oncogene found in 2% of lung adenocarcinomas and represents a target for therapy. We examined the clinical characteristics and course of patients with lung adenocarcinomas harboring BRAF mutations. Methods: We identified patients with lung adenocarcinomas harboring BRAF mutations between 2009 and 2013 detected using a mass spectrometry-based polymerase chain reaction genotyping assay of hot-spot mutations involving codons corresponding to amino acids V600, D594, and G469 of BRAF. Patient characteristics and treatment outcomes were analyzed. Overall survival (OS) was compared with stage-matched patients with KRAS and EGFR mutant lung adenocarcinomas. Results: Sixty-three patients were diagnosed with BRAF mutant lung adenocarcinomas between 2009 and 2013 (V600, 36; non-V600, 27). The majority of patients with BRAF mutations were smokers (92%), although patients with V600 mutations were more likely to be light/never-smokers compared with patients with non-V600 mutations (42% versus 11%; p = 0.007). Of the 32 patients with early-stage disease, six (19%; 95% confidence interval 7%-36%) developed second primary lung cancers harboring KRAS mutations. Patients with advanced V600 mutant lung adenocarcinomas had a better survival from diagnosis compared with those with non-V600 mutant lung adenocarcinomas (3-year OS: 24% versus 0%; p < 0.001). Conclusions: This is the largest series of patients with BRAF mutant lung cancers described. Most patients were heavy smokers. Nineteen percent of patients with early-stage BRAF mutant lung cancers developed second primary lung cancers harboring KRAS mutations. Patients with advanced lung adenocarcinomas harboring V600 mutations have an improved OS compared with those with non-V600 mutations.
Keywords: chemotherapy; adenocarcinoma; gene; melanoma; braf; mek; features; inhibition; 1st-line treatment; somatic mutations; improved survival; lung cancers; open-label; non-small-cell lung cancers
Journal Title: Journal of Thoracic Oncology
Volume: 9
Issue: 11
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2014-11-01
Start Page: 1669
End Page: 1674
Language: English
ACCESSION: WOS:000344368100016
DOI: 10.1097/jto.0000000000000344
PROVIDER: wos
PMCID: PMC4251710
PUBMED: 25436800
Notes: Article -- Source: Wos
Altmetric Score
MSK Authors
  1. Camelia S Sima
    212 Sima
  2. Marc Ladanyi
    973 Ladanyi
  3. Gregory J Riely
    393 Riely
  4. Paul K Paik
    102 Paik
  5. Maria Eugenia Arcila
    415 Arcila
  6. Mark Kris
    688 Kris
  7. Matthew David Hellmann
    224 Hellmann
  8. Anna Maria Litvak
    27 Litvak
  9. Charles Rudin
    203 Rudin
  10. Kaitlin Marie Woo
    100 Woo